Cerebain Biotech Announces General Business Update

Nov. 12, 2020 15:28 UTC

 

 
 

COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announces a General Business Update.

Cerebain is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current.

Upon the completion of the acquisition, Cerebain will initiate a review of its overall business and corporate strategic plan. The corporate strategic initiatives to be developed and implemented include, but are not limited to, rebranding and repositioning of the Company’s overall business plan and a comprehensive growth strategy focused on revenue generation through a comprehensive roll-up acquisition strategy of target qualified candidates in select industries.

About Cerebain Biotech Corp.

Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.

About PKG Inc.

PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps to raise your company to the next level by leveraging our skills in engineering and technology integration across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all their product development and manufacturing needs. In addition to our expertise of system level devices and human machine interfaces, PKG also offers incubation and acceleration services for startup business and entrepreneurs.

Forward Looking Statements

This news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Contacts

Investors:
Mr. Alan Klitenic
Cerebain Biotech Corp.
888.430.2221
info@cerebain.com

 
 

Source: Cerebain Biotech Corp.

Back to news